OCTO Home
Breaking News
VICTOR at ESMO 2008 A presentation looking at recurrence rates in VICTOR patients according to COX-2 genotyping has been accepted for presentation at this year’s ESMO conference in Stockholm (12-16 Sep 2008).
Click here to view the poster
– PDF-File, 60.6 KB
QUASAR V
A statement has been issued regarding the use of TroVax in the QUASAR V trial.
Click here for details.
FOXFIRE
Cancer Research UK has approved funding for the FOXFIRE trial.
We are still looking for sites to take part in this trial, please contact OCTO for more details.
Click here for further details about the trial.
EnROL
The first three sites have been activated to recruit patients into the EnROL trial.
Click here for further details about the trial.
COG
The COG launch will be held at Friends House, London on 22 September 2008.
Click here for details.
AspECT
AspECT is drawing to the end of its recruitment phase. In this last push to get the total recruitment to 2500, we need each site to recruit just 4 patients - i.e. 2 per month. This is easily achievable.
Click here for further details about the trial.
About OCTO
The Oncology Clinical Trials Office (OCTO) is concerned with the practical application of high-quality clinical research into innovative and effective cancer therapies particularly in the field of gastrointestinal cancer.OCTO's key aims are to improve both survival rates and the quality of life of cancer patients by contributing to the evidence-base that will underpin cancer services now and in the future; and to bring about major and continuing improvements in the quality of practice in clinical research. These aims will be achieved in partnership with academic-led research communities, with industry and with patients and their carers.
We aspire to put OCTO on a par with the best in the world, and to establish it as a national and international leader in its approach to the integration of research, treatment and care for cancer patients.
OCTO is part of the Clinical Pharmacology Department of Oxford University.
